|Day Low/High||0.67 / 0.71|
|52 Wk Low/High||0.46 / 1.66|
Shares of Durect Corporation (Nasdaq:DRRX) were gapping down Friday morning with an open price 25.6% lower than Thursday's closing price. The stock closed at $3.09 yesterday and opened today's trading at $2.30.
Pfizer and Pain Therapeutics have been trying to get Remoxy, a tamper-resistant painkiller, approved for three years.
Alcoa's first-quarter earnings squeaked past Wall Street expectations, but its top line missed analysts' estimates.
An updated list of drug and biotech firms with drug approvals expected in 2011.
DURECT Corporation Q1 2010 Earnings Call Transcript
Durect says Transdur Sufentanil reduced pain and met safety goals in midstage clinical trial
Keeping an eye on Seattle Genetics, Dynavax Technologies and Durect.
See what companies our team is considering for the Stocks Under $10 portfolio.
Despite dismal economic data and the threat of inflation, these three names in the under-$10 space are becoming very attractive.
With many of the stocks on our Watch List trading lower, we plan to commit some cash to new positions.
Cortex Pharma climbs on greenlight from the FDA for an Alzheimer's trial.
Wellcare surges after its third-quarter earnings and fourth-quarter guidance top views.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.